BriaPro subsidiary reports net loss of $246K; going concern doubt flagged

BriaCell Therapeutics Corp.

BriaPro incurred net loss of $245,960 for six months ended Jan 31, 2024 (no prior-year comparison).
Assets of $207,432 (mainly intangible patents) offset by $250,678 current liabilities; shareholders' deficit of $231,367.
Going concern note: 'significant doubt' about ability to continue as pre-clinical stage company needs further financing.
Due to parent BriaCell $196,549 under transition services agreement; warrant liability of $188,121 recorded.
Operating loss of $257,057; R&D expenses $168,536 and G&A $88,494 for the six-month period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.